Mortality

Global Liver Cancer Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:40am

The "Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report by Type (Laboratory Tests, Imaging Tests, Endoscopy, Biopsy), by End-use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global liver cancer diagnostics market size is expected to reach USD 17.4 billion by 2028.
  • The rising prevalence of liver cancer and the introduction of innovative diagnosis products are propelling the market growth.
  • The most common cause of liver cancer is chronic (long-term) infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV).

ZOLL Foundation Announces Grant Application Submission Deadline of March 31, 2022

Retrieved on: 
Thursday, January 13, 2022 - 3:00pm

The next submission deadline is March 31, 2022.

Key Points: 
  • The next submission deadline is March 31, 2022.
  • The ZOLL Foundation is eager to provide seed money as an investment in those researchers we believe will make important future contributions.
  • Newly updated application and budget forms are available for the March 31 deadline on the How to Apply page of the Foundation website, https://www.zollfoundation.org/apply/ .
  • The ZOLL Foundation is a 501 (c)(3) non-profit organization that operates independently from ZOLL Medical Corporation.

MoMMA's Voices and AIM Launch the First-Ever Lived Experience Integration™ Into QI Community of Learning in 23 States

Retrieved on: 
Thursday, January 13, 2022 - 1:41pm

"The integration of patients' lived experience into quality improvement teams is critical to the success ofour efforts to decrease preventable maternal morbidity and mortality in the U.S.," said AIM SeniorDirectoratACOG ChristieAllen.

Key Points: 
  • "The integration of patients' lived experience into quality improvement teams is critical to the success ofour efforts to decrease preventable maternal morbidity and mortality in the U.S.," said AIM SeniorDirectoratACOG ChristieAllen.
  • The Lived Experience Integration into QI Community of Learning (COL) training program is an eight-weekeducational series created by MoMMA's Voices and funded by AIM.
  • The program will run January toMay 2022 and will serve three cohorts of 23 AIM state and jurisdiction-based teams, Indian HealthServicesfacilities, andotherhealthcareentities.
  • During the eight-week AIM COL program, each cohort will learn how to effectively build a patientengagement culture centered on the Lived Experience Integration, a concept developed by MoMMA'sVoices.

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

Retrieved on: 
Thursday, January 13, 2022 - 12:00pm

With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.

Key Points: 
  • With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Retrieved on: 
Thursday, January 13, 2022 - 9:00am

The phase 1b/2 open label trial is designed to evaluate safety, tolerability, and anti-tumor activity of the combination in up to 53 patients with advanced NSCLC who have progressed after prior treatment.

Key Points: 
  • The phase 1b/2 open label trial is designed to evaluate safety, tolerability, and anti-tumor activity of the combination in up to 53 patients with advanced NSCLC who have progressed after prior treatment.
  • The trial will also include exploratory biomarker analyses of a novel predictive biomarker and immune cell profiling in response to the treatment.
  • The trial also applies a convenient flat dosing regimen presenting long-term development opportunities for ADG106.
  • A trial in combination with toripalimab is underway in China, and one in combination with pembrolizumab is planned.

Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China

Retrieved on: 
Thursday, January 13, 2022 - 6:15am

This is the second approved indication for oral Cresemba in China, after the approval for the treatment of adult patients with invasive mucormycosis, which was received in December 2021.

Key Points: 
  • This is the second approved indication for oral Cresemba in China, after the approval for the treatment of adult patients with invasive mucormycosis, which was received in December 2021.
  • David Veitch, Basileas CEO said: Invasive aspergillosis is the more frequent infection than mucormycosis and we congratulate our partner Pfizer on this second approval of Cresemba in China, thus broadening the range of approved indications.
  • With this approval, patients in China who are suffering from invasive aspergillosis will now have access to a treatment that can help to address their unmet needs.
  • China is a very important commercial market for Cresemba, accounting for approximately 20 percent of global sales for newer antifungals.

First 5: The Governor Unveiled the 2022-23 Budget Proposal Which Serves as a Framework to Advance the Health and Well-being of California’s Youngest Children

Retrieved on: 
Thursday, January 13, 2022 - 3:09am

On Monday, Governor Newsom released his proposed 2022-23 budget plan, a framework that features important investments to advance the health and well-being of Californias youngest children.

Key Points: 
  • On Monday, Governor Newsom released his proposed 2022-23 budget plan, a framework that features important investments to advance the health and well-being of Californias youngest children.
  • These are critical investments as we continue to confront the historic barriers our families face including racism, injustice, and poverty.
  • We applaud the governor for keeping the needs of parents and children a centerpiece in this years budget, said Camille Maben, executive director at First 5 California.
  • Central to the governors budget proposal is funding for the implementation of previously created supports and services for families.

Global Carrier Screening Market (2021 to 2027) - Featuring Thermo Fisher Scientific, Illumina and Natera Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 12, 2022 - 4:10pm

These factors are anticipated to boost the growth and demand for the carrier screening market during the forecast period.

Key Points: 
  • These factors are anticipated to boost the growth and demand for the carrier screening market during the forecast period.
  • In the last couple of years, the overall carrier screening market has seen huge popularity due to its advantages.
  • Moreover, the adoption rate of carrier screening and testing is expected to increase due to the rise in the number of patients with genetic disorders.
  • However, the dearth of skilled professionals is estimated to hinder the growth of the Carrier Screening Market over the forecast period.

First-Of-Its-Kind Project To Use Private-Sector Funding to Reduce Asthma for NYC Medicaid Recipients

Retrieved on: 
Wednesday, January 12, 2022 - 4:21pm

"This project captures the vision that funding health-based housing interventions to lower the incidence of asthma is critical to addressing the social determinants of health and equity.

Key Points: 
  • "This project captures the vision that funding health-based housing interventions to lower the incidence of asthma is critical to addressing the social determinants of health and equity.
  • The project aims to reduce serious asthma episodes among 850 children and adults who have chronic asthma.
  • Helping people with asthma manage these issues earlier will reduce costs by preventing avoidable emergency department visits and hospitalizations.
  • Estimates indicate that the project will result in $6.5 million in healthcare savings which more than compensates for the initial investment.

First Stop Health Launches Virtual Primary Care to Treat Urgent, Preventive and Chronic Care Issues

Retrieved on: 
Wednesday, January 12, 2022 - 3:04pm

"FSH Virtual Primary Care can prevent medical claims now with 24/7 urgent care and reduce claims risk later with effective primary care for chronic disease and prevention - which is all available virtually for members."

Key Points: 
  • "FSH Virtual Primary Care can prevent medical claims now with 24/7 urgent care and reduce claims risk later with effective primary care for chronic disease and prevention - which is all available virtually for members."
  • FSH Virtual Primary Care is available via app, website or phone to help improve members' health by delivering whole-person, digital-first care.
  • Virtual Primary Care members can schedule virtual visits with a preferred doctor from within the FSH virtual group practice.
  • We help them save time and money with safe, convenient, high-quality virtual care solutions - Telemedicine, Virtual Mental Health and Virtual Primary Care.